

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

|       |   |    |   |                        |                  |
|-------|---|----|---|------------------------|------------------|
| Sheet | 1 | of | 1 | Attorney Docket Number | 09797.0002-00000 |
|-------|---|----|---|------------------------|------------------|

**U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS**

| Examiner Initials | Cite No. <sup>1</sup> | Document Number                          | Issue or Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-------------------|-----------------------|--|---|---|---|
|                   |                       | Number-Kind Code <sup>2</sup> (if known) |   |   |   |
|                   |                       | US-                                      |   |   |   |
|                   |                       | US-                                      |   |   |   |
|                   |                       | US-                                      |   |   |   |

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

**FOREIGN PATENT DOCUMENTS**

| Examiner Initials | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | Translation <sup>6</sup> |
|-------------------|-----------------------|---|--------------------------------|---|---|--------------------------|
|                   |                       | Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) |                                |   |   |                          |
| 1                 | WO 02/057425          |   | 07-25-2002                     | Merck & Co., Inc.<br>Isis Pharmaceuticals, Inc. |   |                          |
|                   |                       |   |                                |   |   |                          |

**NONPATENT LITERATURE DOCUMENTS**

|                   |                       |   |                          |
|-------------------|-----------------------|---|--------------------------|
| Examiner Initials | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation <sup>6</sup> |
|                   | 2                     | EWING, DF et al. "Novel reversed cyclonucleoside analogues with a D-ribofuranose glycone," <i>Carbohydrate Research</i> , 321: 190-196 (1999).  |                          |
|                   |                       |   |                          |
|                   |                       |   |                          |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.